Novartis (NVS) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Novartis (NVS) has outperformed Pfizer (PFE) over the past year, gaining 18.2% versus a gain of 9.4%. Over five years, NVS leads with a +86.5% price change compared with -49.3% for PFE. Novartis is the larger company by market cap ($284.18 billion vs $156.18 billion), about 1.8 times the size.
On valuation, Pfizer trades at a lower forward P/E (9.3x vs 15.1x for Novartis). Pfizer offers the higher dividend yield (7.85% vs 3.10%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVS | PFE |
|---|---|---|
| Share price | $150.47 | $27.40 |
| Market cap | $284.18B | $156.18B |
| 1-day change | -0.50% | -0.51% |
| YTD return | +9.14% | +10.04% |
| 1-year return | +18.19% | +9.42% |
| 5-year return | +86.46% | -49.26% |
| P/E ratio (TTM) | 28.72 | 39.14 |
| Forward P/E | 15.15 | 9.28 |
| EPS (TTM) | $5.24 | $0.70 |
| Dividend yield | 3.10% | 7.85% |
| Annual dividend | $4.67 | $2.15 |
| Revenue (latest FY) | — | $62.58B |
| Revenue growth (YoY) | — | -1.65% |
| Net income (latest FY) | $13.98B | $7.77B |
| Gross margin | — | 74.33% |
| Net margin | — | 12.42% |
| 52-week high | $170.46 | $31.44 |
| 52-week low | $126.50 | $23.62 |
| Distance from 52-week high | -11.73% | -12.85% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +4.41% | +10.29% |
| Average volume | 2.18M | 33.52M |
| Shares outstanding | 1.89B | 5.70B |
| Employees | 75,267 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pfizer trades at a higher earnings multiple (39.1x vs 28.7x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (7.85% vs 3.10%).
About Novartis
NVS stock →Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
NVS vs PFE FAQ
Which is bigger, Novartis or Pfizer?
Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $156.18B for Pfizer (PFE).
Which stock has performed better over the past year, NVS or PFE?
NVS returned +18.19% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NVS or PFE?
NVS has the lower trailing P/E at 28.7, versus 39.1 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Novartis or Pfizer?
Pfizer has the higher yield at 7.85%, compared with 3.10% for Novartis.
Are Novartis and Pfizer in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.